ORIENT BIO Inc. (KRX:002630)
1,780.00
+160.00 (9.88%)
Feb 21, 2025, 9:00 AM KST
ORIENT BIO Revenue
ORIENT BIO had revenue of 17.21B KRW in the quarter ending December 31, 2021, with 21.77% growth. This brings the company's revenue in the last twelve months to 59.09B, up 19.53% year-over-year. In the fiscal year ending March 31, 2021, ORIENT BIO had annual revenue of 52.02B with 39.79% growth.
Revenue (ttm)
59.09B
Revenue Growth
+19.53%
P/S Ratio
3.38
Revenue / Employee
472.73M
Employees
125
Market Cap
200.02B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2021 | 52.02B | 14.81B | 39.79% |
Mar 31, 2020 | 37.21B | 6.84B | 22.52% |
Mar 31, 2019 | 30.37B | 4.75B | 18.53% |
Mar 31, 2018 | 25.62B | -83.39B | -76.50% |
Mar 31, 2017 | 109.02B | 3.97B | 3.78% |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Mar 31, 2014 | Pro | Pro | Pro |
Mar 31, 2013 | Pro | Pro | Pro |
Mar 31, 2012 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,364.39B |
Celltrion | 2,876.25B |
Yuhan | 2,008.84B |
SK Biopharmaceuticals | 511.33B |
SK bioscience | 201.30B |
Hanmi Pharm. | 1,495.50B |
Peptron | 2.41B |
Hanall Biopharma | 134.24B |